-
Mashup Score: 2
Neuropathy is an adverse effect that can occur when enfortumab veodtin is administered to patients with locally advanced or metastatic urothelial carcinoma.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Data from the phase 3 EV-302 trial support an application for enfortumab vedotin plus pembrolizumab as a treatment for patients with advanced bladder cancer in China.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0EV-302 Study Design and Results - 1 month(s) ago
Thomas Powles, MBBS, MRCP, MD, joins the Oncology Brothers to discuss the study design and results of the EV-302 trial investigating enfortumab vedotin plus pembrolizumab in untreated advanced urothelial carcinoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Exploring the THOR Study of Erdafitinib in Advanced Bladder Cancer - 2 month(s) ago
Arlene O. Siefker-Radtke, MD, dives into the background and the cohorts included in the phase 3 THOR study.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6Treatment Algorithm for Non–Muscle-Invasive Bladder Cancer (NMIBC) - 2 month(s) ago
Sia Daneshmand, MD, and Karine Tawagi, MD, join Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for non–muscle-invasive bladder cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the recent approval of nivolumab plus chemotherapy for patients with unresectable or metastatic urothelial carcinoma.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1ICI Outcomes Better in PD-L1-Positive Metastatic Urothelial Carcinoma - Renal and Urology News - 2 month(s) ago
Investigators report findings from a systematic review and meta-analysis of 14 studies.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0Enfortumab Vedotin Maintains HRQoL in Pretreated Advanced Urothelial Carcinoma - Renal and Urology News - 2 month(s) ago
Patients treated with enfortumab vedotin vs chemotherapy reported greater pain reduction but worse appetite loss.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 3Adjuvant Therapy in Bladder Cancer: Real-World vs Clinical Trials - 2 month(s) ago
Alex Chehrazi-Raffle, MD, discussed a real-world analysis of clinical characteristics of patients with bladder cancer receiving adjuvant nivolumab or chemotherapy.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Systemic Therapy Alone Linked to Worse Survival in Advanced Bladder Cancer - Renal and Urology News - 3 month(s) ago
More extensive lymph node dissection was significantly associated with better survival.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
Kirollos S. Hanna, PharmD, BCPS, BCOP, FACC, spoke about the AE associated with enfortumab vedotin plus pembrolizumab in locally advanced or metestatic urothelial carcinoma and how clinicians can become better aware of them. #blcsm | @KirollosPharmD https://t.co/jHQgWlWOYU